首页 | 本学科首页   官方微博 | 高级检索  
     


A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Affiliation:1. Tumour Identity Card Program (CIT), French League Against Cancer, Paris, France;2. Cancer Research Center of Marseille, CRCM, Inserm, CNRS, Paoli-Calmettes Institut, Aix-Marseille University, Marseille, France;3. Nord Hospital, Marseille, France;4. Laboratory of Experimental Gastroenterology (Université Libre de Bruxelles), Brussels, Belgium;5. Department of Gastroenterology and Digestive Oncology, Delta Hospital, Center Hospitalier Interregional Edith Cavell, Brussels, Belgium;6. Sorbonne University, UPMC University, Department of Gastroenterology, Pitié-Salpetriére Hospital, Paris, France;7. Ambroise Paré Hospital, Boulogne, AP-HP, Boulogne-Billancourt, France;8. Department of Digestive Oncology, Beaujon Hospital, Paris 7 University, APHP, Clichy, France;9. Paoli-Calmettes Institut, Marseille, France;10. La Timone Hospital, Marseille, France
Abstract:
Keywords:pancreatic cancer  gemcitabine  chemosensitivity prediction  transcriptomic signature  precision medicine
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号